Flerie Expands Access to Private Life Science Investments for Swedish Investors

Flerie, under CEO Ted Fjällman, is pioneering an investment approach that grants investors exclusive access to private life science companies, a sector typically hard to reach and fraught with risk and diversification challenges. The firm's portfolio includes 25 life science companies, with 17 based in Sweden, focusing on therapeutic areas such as heart failure, cancer, metabolic diseases, and rare conditions. Notably, 77% of Flerie's capital is locked in private firms, highlighting its emphasis on early-stage biotech projects that are moving towards clinical proof-of-concept and companies in commercial growth phases with market-ready products.

The firm's investment strategy combines an evergreen model—providing continuous support for value-generating companies—with active portfolio management to prioritize the most promising projects. This is supported by a strong global network of syndicate investors across Europe, the USA, and Asia, ensuring funding even amid challenging market conditions. Since its Nasdaq Stockholm listing in June 2024, interest in life science investments has surged, underscoring Flerie's role in making this high-potential sector more accessible and less risky for investors.

CEO Ted Fjällman expresses optimism about the future, stressing that Flerie's model balances access, risk, and innovation, enabling investors to support life-changing technologies without bearing disproportionate exposure. The firm's portfolio also benefits from recent growth investments in companies like NorthX Biologics, enhancing capabilities in biological drug development and manufacturing.